Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Palvella Therapeutics (NASDAQ:PVLA – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Palvella Therapeutics in a research report ...

Brandon Lutnick, a trader at his father’s Cantor Fitzgerald LP, has been listed as CEO at its most recently created SPAC, Cantor Equity Partners I Inc., according to a filing Wednesday.

Brandon Lutnick, a trader at his father’s Cantor Fitzgerald LP, has been listed as CEO at its most recently created SPAC, Cantor Equity Partners I Inc., according to a filing Wednesday. The entity, ...

Trader Brandon Lutnick, 26, to run a new blank-check vehicle His father is giving up posts to join Trump’s administration Donald Trump’s commerce secretary nominee, Howard Lutnick, is taking a key ...

Cantor Fitzgerald CEO Howard Lutnick, the president-elect’s pick for commerce secretary, has purchased the Washington, D.C., home of Fox News anchor Bret Baier for $25 million.

Proud mother Yasmien Kurdi expressed a deep love for her daughter Ayesha. Yasmien Kurdi is turning a challenging moment into a powerful celebration of strength and love. In a Facebook post, the ...

Cantor Fitzgerald raised its price target for the company Archer Aviation (ACHR, Financial) on Wednesday to $13.00 from $10.00, which pushed Archer stock soared 8% on Wednesday. This helped ...

With that in mind, Digital Foundry's Oliver Mackenzie spoke to PS5 Pro lead system architect Mark Cerny and core technology director at Insomniac Games, Mike Fitzgerald. This tech interview covers ...

On Tuesday, Cantor Fitzgerald initiated coverage on Esperion (NASDAQ:ESPR) Therapeutics, a biopharmaceutical company, with an Overweight rating and a price target of $8.00. The firm pointed out the ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol ...

On Tuesday, Cantor Fitzgerald initiated coverage on Esperion (NASDAQ:ESPR) Therapeutics, a biopharmaceutical company, with an Overweight rating and a price target of $8.00. The firm pointed out ...